The IPO Paradox: Why Biotech Firms Are Flocking to Hong Kong A US based firm developing cutting edge therapies for infant brain injuries is planning an initial public offering (IPO) in Hong Kong, a trend that reflects growing interest in the city state as a hub for biotech innovation.
Axiom Biosciences will list on the Hong Kong Stock Exchange in 2027 and follow up with a secondary listing in the US two years later.
Hong Kong's reputation as a favorable destination for biotech companies is due in part to its more accommodating regulatory environment compared to the US.